Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 42% Improvement Relative Risk c19hcq.org Wiseman et al. HCQ for COVID-19 META ANALYSIS Favors HCQ Favors control
Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data
Wiseman et al., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis)
Wiseman et al., Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective.., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis)
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p=0.044, for the original trial 3 day specification.
Currently there are 9 HCQ post-exposure prophylaxis studies and meta analysis shows:
OutcomeImprovement
Mortality46% lower [-80‑84%]
Hospitalization16% lower [-69‑58%]
Cases24% fewer [0‑41%]
risk of case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wiseman et al., 2 Dec 2020, preprint, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.11.29.20235218; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Effective post-exposure prophylaxis of Covid-19 associated with hydroxychloroquine: Prospective dataset reanalysis incorporating novel, missing data Running Title: Postexposure hydroxychloroquine Covid-19 prophylaxis: Reanalysis, missing data David M. Wiseman, PhD, MRPharmS;a Pierre Kory, MD, MPA;b Samir A Saidi, PhD, MB ChB;c Dan Mazzucco, PhD.d a Synechion, b Aurora Inc., Dallas, TX, USA St. Luke’s Medical Center, Milwaukee, WI, USA. and Front Line Critical Care Alliance. pierrekory@icloud.com c Central d Clinic School, University of Sydney, Australia, sam.saidi@sydney.edu.au Third Eye Associates, Cherry Hill, NJ, USA. dmazzucco@zsxmedical.com Address for correspondence: Dr. David Wiseman, Synechion, Inc., 18208 Preston Road, Suite D9-405, Dallas, 75252 synechion@aol.com Telephone: 972 931 5596 Fax: 972 931 5476 Word count: 3989 words Funding source: None ORCID DMW 0000-0002-8367-6158 PK 0000-0002-0816-9682 SAS 0000-0001-5165-2461 DM 0000-0003-3578-4610 NOTE: preprint reports new research thatCOVID-19 has not beenpost-exposure certified by peer prophylaxis review and should not be used to guide clinical practice. Wiseman et al.This Exploratory reanalysis – HCQ: REV070221 Page 1 of 28 medRxiv preprint doi: https://doi.org/10.1101/2020.11.29.20235218; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract BACKGROUND: A key trial (NCT04308668) of post-exposure prophylaxis found hydroxychloroquine-associated (HCQ) reductions of Covid-19 by 17% overall and 31% to 49% in subgroups. To understand these trends, we reanalyzed the dataset. METHODS: Our protocol conformed to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). We compared the incidence of Covid-19 after HCQ or placebo, stratifying by intervention lag, age, and gender. RESULTS: Newly requested data missing from the dataset revealed that 52% and 19% of subjects received medication 1-2 days after intended and assumed overnight delivery or four-day intervention lag respectively. After re-analysis, we found reduced HCQ-associated incidence of Covid-19 with Early (up to 3 days post-exposure) (RR 0.58, 95%CI 0.35 - 0.97; p=0.044; NNT 14.5) but not Late (RR 1.22, 95%CI 0.72 - 2.04) prophylaxis. We found a significant HCQ-associated Covid-19 reduction in subjects 18 to 45 years old with Early (RR 0.54, 95%CI 0.29-0.97; p=0.0448, NNT 11.5) but not Late (RR 1.02, 95%CI 0.55-1.89) prophylaxis, attenuated in older subjects (RR 0.75, 95%CI 0-27-2.05) and by co-morbidities. Although, we did not detect effects of gender, folate, zinc, or ascorbate, confounding effects cannot be excluded. CONCLUSIONS: Using novel data and prospective re-analysis, hydroxychloroquine, in an age-dependent manner, was associated with reduced Covid-19 compatible illness when supplied for post-exposure prophylaxis between 1 and 3 days after high- or moderate-risk exposure, at higher loading and..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit